Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes

Area of Science:

• Rheumatology
• Hepatology
• Autoimmune Diseases

Background:

• Limited longitudinal prognostic data exist for systemic sclerosis (SSc) patients with coexisting primary biliary cholangitis (PBC).
• Cross-sectional studies have described patient characteristics, but long-term outcomes remain under-researched.

Purpose of the Study:

• To characterize the phenotype of SSc-PBC patients, including baseline features and clinical outcomes.
• To compare the progression and prognosis of SSc with and without PBC.

Main Methods:

• A multicenter European Scleroderma Trials and Research Group study.
• Matched cohort design comparing SSc-PBC patients with SSc patients without hepatobiliary involvement.
• Data collection at baseline and last available visit.

Main Results:

• SSc-PBC patients showed a higher prevalence of anti-centromere antibodies and less severe vascular involvement (fewer digital ulcers) compared to SSc-only patients.
• SSc patients without PBC had a higher incidence of pulmonary arterial hypertension and conduction blocks.
• PBC patients exhibited higher baseline liver enzymes, which significantly decreased at follow-up; one patient underwent liver transplantation.

Conclusions:

• The co-occurrence of SSc and PBC is associated with a generally mild phenotype for both conditions.
• Outcomes for SSc-PBC patients are favorable, with reduced vascular complications and improved liver enzyme profiles over time.